Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

The Authors Reply.

Solis M, Velay A, Moulin B, Caillard S, Fafi-Kremer S.

J Am Soc Nephrol. 2018 May;29(5):1578. doi: 10.1681/ASN.2018010027. Epub 2018 Feb 21. No abstract available.

PMID:
29467142
2.

Distribution and reduction magnitude of HIV-DNA burden in CD4+ T cell subsets depend on art initiation timing.

Gantner P, Barnig C, Partisani M, Lee GQ, Beck-Wirth G, Faller JP, Martinot M, Mosheni-Zadeh M, Cheneau C, Batard ML, Fischer P, Fuchs A, Uring-Lambert B, Bahram S, Rey D, Fafi-Kremer S.

AIDS. 2018 Apr 24;32(7):921-926. doi: 10.1097/QAD.0000000000001770.

PMID:
29424775
3.

Comparison of six commercial tick-borne encephalitis IgM and IgG ELISA kits and the molecular characterization of their antigenic design.

Velay A, Solis M, Barth H, Sohn V, Moncollin A, Neeb A, Wendling MJ, Fafi-Kremer S.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):286-292. doi: 10.1016/j.diagmicrobio.2017.12.012. Epub 2017 Dec 22.

PMID:
29366629
4.

Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant.

Soulie C, Morand-Joubert L, Cottalorda J, Charpentier C, Bellecave P, Le Guen L, Yerly S, Montes B, Fafi-Kremer S, Dina J, Avettand-Fenoel V, Amiel C, Roussel C, Pallier C, Zafilaza K, Sayon S, Signori-Schmuck A, Mirand A, Trabaud MA, Berger S, Calvez V, Marcelin AG; ANRS AC11 resistance group.

J Clin Virol. 2018 Feb - Mar;99-100:57-60. doi: 10.1016/j.jcv.2017.12.014. Epub 2018 Jan 8.

PMID:
29331843
5.

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Gantner P, Lee GQ, Rey D, Mesplede T, Partisani M, Cheneau C, Beck-Wirth G, Faller JP, Mohseni-Zadeh M, Martinot M, Wainberg MA, Fafi-Kremer S.

J Antimicrob Chemother. 2018 Apr 1;73(4):1045-1053. doi: 10.1093/jac/dkx475.

PMID:
29244129
6.

Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.

Solis M, Velay A, Porcher R, Domingo-Calap P, Soulier E, Joly M, Meddeb M, Kack-Kack W, Moulin B, Bahram S, Stoll-Keller F, Barth H, Caillard S, Fafi-Kremer S.

J Am Soc Nephrol. 2018 Jan;29(1):326-334. doi: 10.1681/ASN.2017050532. Epub 2017 Oct 17.

PMID:
29042457
7.

A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016.

Velay A, Solis M, Kack-Kack W, Gantner P, Maquart M, Martinot M, Augereau O, De Briel D, Kieffer P, Lohmann C, Poveda JD, Cart-Tanneur E, Argemi X, Leparc-Goffart I, de Martino S, Jaulhac B, Raguet S, Wendling MJ, Hansmann Y, Fafi-Kremer S.

Ticks Tick Borne Dis. 2018 Jan;9(1):120-125. doi: 10.1016/j.ttbdis.2017.09.015. Epub 2017 Sep 28.

PMID:
28988602
8.

Congenital Lymphocytic Choriomeningitis Virus: A Case of Prenatal Diagnosis.

Delaine M, Weingertner AS, Nougairede A, Lepiller Q, Fafi-Kremer S, Favre R, Charrel R.

J Ultrasound Med. 2018 Mar;37(3):804-806. doi: 10.1002/jum.14372. Epub 2017 Aug 29. No abstract available.

PMID:
28858375
9.

Microcephaly Caused by Lymphocytic Choriomeningitis Virus.

Delaine M, Weingertner AS, Nougairede A, Lepiller Q, Fafi-Kremer S, Favre R, Charrel R.

Emerg Infect Dis. 2017 Sep;23(9):1548-1550. doi: 10.3201/eid2309.170775.

10.

Peculiar Clinical Presentation of Coxsackievirus B4 Infection: Neonatal Restrictive Cardiomyopathy.

Le Van Quyen P, Desprez P, Livolsi A, Lindner V, Fafi-Kremer S, Helms P, Antal MC.

AJP Rep. 2017 Apr;7(2):e124-e126. doi: 10.1055/s-0037-1601352. Epub 2017 Jun 29.

11.

Performance of the Liaison® XL Murex recHTLV-I/II Immunoassay in the Detection of HTLV-1/2 Antibodies in Serum.

Gantner P, Velay A, Guigue N, Barth H, Wendling MJ, Delaugerre C, Fafi-Kremer S.

Clin Lab. 2017 May 1;63(5):997-1001. doi: 10.7754/Clin.Lab.2017.161026.

12.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
13.

Efficacy and safety of dolutegravir and rilpivirine dual therapy as a simplification strategy: a cohort study.

Gantner P, Cuzin L, Allavena C, Cabie A, Pugliese P, Valantin MA, Bani-Sadr F, Joly V, Ferry T, Poizot-Martin I, Garraffo R, Peytavin G, Fafi-Kremer S, Rey D; Dat'AIDS study group.

HIV Med. 2017 Oct;18(9):704-708. doi: 10.1111/hiv.12506. Epub 2017 Apr 26. No abstract available.

PMID:
28444816
14.

Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient.

Velay A, Kack-Kack W, Abravanel F, Lhomme S, Leyendecker P, Kremer L, Chamouard P, Izopet J, Fafi-Kremer S, Barth H.

J Neurovirol. 2017 Aug;23(4):615-620. doi: 10.1007/s13365-017-0525-0. Epub 2017 Apr 24.

PMID:
28439773
15.

Problem-based learning in laboratory medicine resident education: a satisfaction survey.

Lepiller Q, Solis M, Velay A, Gantner P, Sueur C, Stoll-Keller F, Barth H, Fafi-Kremer S.

Ann Biol Clin (Paris). 2017 Apr 1;75(2):181-192. doi: 10.1684/abc.2017.1236.

PMID:
28377331
16.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773. doi: 10.1093/jac/dkx042.

PMID:
28333232
17.

45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.

Barth H, Solis M, Lepiller Q, Sueur C, Soulier E, Caillard S, Stoll-Keller F, Fafi-Kremer S.

Crit Rev Microbiol. 2017 Mar;43(2):178-195. doi: 10.1080/1040841X.2016.1189873. Epub 2016 Nov 1. Review.

PMID:
27800693
18.

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection.

Barth H, Solis M, Kack-Kack W, Soulier E, Velay A, Fafi-Kremer S.

Viruses. 2016 Oct 22;8(10). pii: E292. Review.

19.

[Tick-borne encephalitis in a child in a nonendemic country: A case report].

Levy M, Abi-Warde MT, Rameau AC, Fafi-Kremer S, Hansmann Y, Fischbach M, Higel L.

Arch Pediatr. 2016 Oct;23(10):1055-1058. doi: 10.1016/j.arcped.2016.06.018. Epub 2016 Sep 15. French.

PMID:
27642148
20.

Long-term storage and safe retrieval of human papillomavirus DNA using FTA elute cards.

Barth H, Morel A, Mougin C, Averous G, Legrain M, Fender M, Risch S, Fafi-Kremer S, Velten M, Oudet P, Baldauf JJ, Stoll-Keller F.

J Virol Methods. 2016 Mar;229:60-5. doi: 10.1016/j.jviromet.2015.12.010. Epub 2015 Dec 23.

PMID:
26721377
21.

Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.

Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P.

Hepatology. 2016 Apr;63(4):1120-34. doi: 10.1002/hep.28428. Epub 2016 Feb 22.

PMID:
26710081
22.

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.

Gantner P, Morand-Joubert L, Sueur C, Raffi F, Fagard C, Lascoux-Combe C, Salmon D, Amiel C, Lambert-Niclot S, Fofana DB, Viard JP, Fafi-Kremer S, Rouzioux C, Avettand-Fenoel V, Ghosn J.

J Antimicrob Chemother. 2016 Mar;71(3):751-61. doi: 10.1093/jac/dkv395. Epub 2015 Dec 16.

PMID:
26676973
23.

Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement.

Solis M, Meddeb M, Sueur C, Domingo-Calap P, Soulier E, Chabaud A, Perrin P, Moulin B, Bahram S, Stoll-Keller F, Caillard S, Barth H, Fafi-Kremer S; French BKV Study Group.

J Clin Microbiol. 2015 Dec;53(12):3842-52. doi: 10.1128/JCM.02145-15. Epub 2015 Oct 14.

24.

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.

Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M; Dat’AIDS study group.

AIDS. 2015 Aug 24;29(13):1665-71. doi: 10.1097/QAD.0000000000000723.

PMID:
26372277
25.

HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.

Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups.

J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26.

PMID:
25885327
26.

Clinical relevance of herpes simplex virus viremia in Intensive Care Unit patients.

Lepiller Q, Sueur C, Solis M, Barth H, Glady L, Lefebvre F, Fafi-Kremer S, Schneider F, Stoll-Keller F.

J Infect. 2015 Jul;71(1):93-100. doi: 10.1016/j.jinf.2015.02.013. Epub 2015 Mar 4.

PMID:
25749257
27.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS Resistance AC11 Group.

J Antimicrob Chemother. 2015 Feb;70(2):566-72. doi: 10.1093/jac/dku419. Epub 2014 Oct 25.

PMID:
25344810
28.

Toward standardization of BK virus monitoring: evaluation of the BK virus R-gene kit for quantification of BK viral load in urine, whole-blood, and plasma specimens.

Sueur C, Solis M, Meddeb M, Soulier E, Domingo-Calap P, Lepiller Q, Freitag R, Bahram S, Caillard S, Barth H, Stoll-Keller F, Fafi-Kremer S.

J Clin Microbiol. 2014 Dec;52(12):4298-304. doi: 10.1128/JCM.02031-14. Epub 2014 Oct 8.

29.

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.

Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D.

Scand J Infect Dis. 2014 Dec;46(12):838-45. doi: 10.3109/00365548.2014.947318. Epub 2014 Sep 17.

PMID:
25229167
30.

Epstein-Barr virus infection and clinical outcome in breast cancer patients correlate with immune cell TNF-α/IFN-γ response.

Marrão G, Habib M, Paiva A, Bicout D, Fallecker C, Franco S, Fafi-Kremer S, Simões da Silva T, Morand P, Freire de Oliveira C, Drouet E.

BMC Cancer. 2014 Sep 11;14:665. doi: 10.1186/1471-2407-14-665.

31.

Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.

Gantner P, Reinhart S, Partisani M, Baldeyrou M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Fafi-Kremer S, Muret P, Rey D.

HIV Med. 2015 Feb;16(2):132-6. doi: 10.1111/hiv.12183. Epub 2014 Aug 15.

32.

High incidence but low burden of coronaviruses and preferential associations between respiratory viruses.

Lepiller Q, Barth H, Lefebvre F, Herbrecht R, Lutz P, Kessler R, Fafi-Kremer S, Stoll-Keller F.

J Clin Microbiol. 2013 Sep;51(9):3039-46. doi: 10.1128/JCM.01078-13. Epub 2013 Jul 12.

33.

Hepatitis C virus vaccines--progress and perspectives.

Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S.

Microb Pathog. 2013 May;58:66-72. doi: 10.1016/j.micpath.2013.02.005. Epub 2013 Mar 7. Review.

PMID:
23499591
34.

Hepatitis C virus envelope glycoprotein signatures are associated with treatment failure and modulation of viral entry and neutralization.

Schvoerer E, Moenne-Loccoz R, Murray JM, Velay A, Turek M, Fofana I, Fafi-Kremer S, Erba AC, Habersetzer F, Doffoël M, Gut JP, Donlin MJ, Tavis JE, Zeisel MB, Stoll-Keller F, Baumert TF.

J Infect Dis. 2013 Apr 15;207(8):1306-15. doi: 10.1093/infdis/jit032. Epub 2013 Jan 18.

PMID:
23335805
35.

Neutralizing antibodies and pathogenesis of hepatitis C virus infection.

Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q, Fofana I, Heydmann L, Stoll-Keller F, Baumert TF.

Viruses. 2012 Oct 9;4(10):2016-30. doi: 10.3390/v4102016. Review.

36.

Challenges for HCV vaccine development in HIV-HCV coinfection.

Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S.

Expert Rev Vaccines. 2012 Jul;11(7):791-804. doi: 10.1586/erv.12.52. Review.

PMID:
22913257
37.

Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies.

Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, Turek M, Heydmann L, Cury K, Hayer J, Combet C, Cosset FL, Pietschmann T, Hiet MS, Bartenschlager R, Habersetzer F, Doffoël M, Keck ZY, Foung SKH, Zeisel MB, Stoll-Keller F, Baumert TF.

Gastroenterology. 2012 Jul;143(1):223-233.e9. doi: 10.1053/j.gastro.2012.04.006. Epub 2012 Apr 10.

38.

Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.

Lacek K, Vercauteren K, Grzyb K, Naddeo M, Verhoye L, Słowikowski MP, Fafi-Kremer S, Patel AH, Baumert TF, Folgori A, Leroux-Roels G, Cortese R, Meuleman P, Nicosia A.

J Hepatol. 2012 Jul;57(1):17-23. doi: 10.1016/j.jhep.2012.02.018. Epub 2012 Mar 10.

PMID:
22414763
39.

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.

Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF.

J Hepatol. 2011 Mar;54(3):566-76. doi: 10.1016/j.jhep.2010.10.014. Epub 2010 Nov 11. Review.

40.

Hepatitis C virus entry and glucocorticosteroids.

Fafi-Kremer S, Habersetzer F, Baumert TF.

J Hepatol. 2010 Dec;53(6):1148-50. doi: 10.1016/j.jhep.2010.07.007. Epub 2010 Aug 11. No abstract available.

41.

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.

Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, Leroux-Roels G, Patel AH, Cosset FL, Pessaux P, Doffoël M, Wolf P, Stoll-Keller F, Baumert TF.

J Exp Med. 2010 Aug 30;207(9):2019-31. doi: 10.1084/jem.20090766. Epub 2010 Aug 16.

42.

Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.

Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ, McKeating JA, Dragic T, Pessaux P, Stoll-Keller F, Schuster C, Thompson J, Baumert TF.

Gastroenterology. 2010 Sep;139(3):953-64, 964.e1-4. doi: 10.1053/j.gastro.2010.05.073. Epub 2010 Jun 2.

43.

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.

Keymeulen B, Candon S, Fafi-Kremer S, Ziegler A, Leruez-Ville M, Mathieu C, Vandemeulebroucke E, Walter M, Crenier L, Thervet E, Legendre C, Pierard D, Hale G, Waldmann H, Bach JF, Seigneurin JM, Pipeleers D, Chatenoud L.

Blood. 2010 Feb 11;115(6):1145-55. doi: 10.1182/blood-2009-02-204875. Epub 2009 Dec 9.

44.

EBV limbic encephalitis after allogenic hematopoietic stem cell transplantation.

Kremer S, Matern JF, Bilger K, Lioure B, Fornecker Y, Stoll-Keller F, Namer IJ, Dietemann JL, Fafi-Kremer S.

J Neuroradiol. 2010 Jul;37(3):189-91. doi: 10.1016/j.neurad.2009.10.001. Epub 2009 Dec 2.

45.

Adaptive immunity to hepatitis C virus.

Zeisel MB, Fafi-Kremer S, Robinet E, Habersetzer F, Baumert TF, Stoll-Keller F.

Viruses. 2009 Sep;1(2):276-97. doi: 10.3390/v1020276. Epub 2009 Sep 8.

46.

[Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].

Stoll-Keller F, Fafi-Kremer S, Wolf P, Doffoël M, Baumert T.

Bull Acad Natl Med. 2008 Nov;192(8):1657-67; discussion 1667-8. Review. French. Erratum in: Bull Acad Natl Med. 2009 Jun;193(6):1359-60.

PMID:
19445379
47.

Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study.

Amiel C, Legoff J, Lescure FX, Coste-Burel M, Deback C, Fafi-Kremer S, Gueudin M, Lafon ME, Leruez-Ville M, Mengelle C, Payan C, Pillet S.

J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9. doi: 10.1097/QAI.0b013e31819a22ec. No abstract available.

PMID:
19322036
48.

Development of hepatitis C virus vaccines: challenges and progress.

Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF.

Expert Rev Vaccines. 2009 Mar;8(3):333-45. doi: 10.1586/14760584.8.3.333. Review.

49.

Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients.

Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E.

World J Gastroenterol. 2009 Feb 14;15(6):753-5.

50.

Frequent compartmentalization of hepatitis C virus with leukocyte-related amino acids in the setting of liver transplantation.

Schramm F, Soulier E, Royer C, Weitten T, Fafi-Kremer S, Brignon N, Meyer N, Ellero B, Woehl-Jaegle ML, Meyer C, Wolf P, Doffoël M, Baumert TF, Stoll-Keller F, Schvoerer E.

J Infect Dis. 2008 Dec 1;198(11):1656-66. doi: 10.1086/592986.

PMID:
18925843

Supplemental Content

Loading ...
Support Center